Literature DB >> 12871669

Microtubule-interacting drugs for cancer treatment.

Paula M Checchi1, James H Nettles, Jun Zhou, James P Snyder, Harish C Joshi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12871669     DOI： 10.1016/S0165-6147(03)00161-5

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN： 0165-6147            Impact factor:   14.819


× No keyword cloud information.
  42 in total

1.  Induction of cytokinesis is independent of precisely regulated microtubule dynamics.

Authors:  Laila I Strickland; Erin J Donnelly; David R Burgess
Journal:  Mol Biol Cell       Date:  2005-07-12       Impact factor: 4.138

2.  Molecular evidence for apoptosis in microfilariae of Wuchereria bancrofti induced by diethylcarbamazine.

Authors:  C A Peixoto; A C O Santos; C F J Ayres
Journal:  Parasitol Res       Date:  2008-05-23       Impact factor: 2.289

3.  Novel third-generation water-soluble noscapine analogs as superior microtubule-interfering agents with enhanced antiproliferative activity.

Authors:  Maged Henary; Lakshminarayana Narayana; Shazia Ahad; Sushma R Gundala; Rao Mukkavilli; Vibhuti Sharma; Eric A Owens; Yogesh Yadav; Mulpuri Nagaraju; Donald Hamelberg; Vibha Tandon; Dulal Panda; Ritu Aneja
Journal:  Biochem Pharmacol       Date:  2014-08-11       Impact factor: 5.858

4.  6-MOMIPP, a novel brain-penetrant anti-mitotic indolyl-chalcone, inhibits glioblastoma growth and viability.

Authors:  Shengnan Du; Jeffrey G Sarver; Christopher J Trabbic; Paul W Erhardt; Allen Schroering; William A Maltese
Journal:  Cancer Chemother Pharmacol       Date:  2018-11-13       Impact factor: 3.333

5.  Design, synthesis and biological evaluation of di-substituted noscapine analogs as potent and microtubule-targeted anticancer agents.

Authors:  Ram C Mishra; Sushma R Gundala; Prasanthi Karna; Manu Lopus; Kamlesh K Gupta; Mulpuri Nagaraju; Donald Hamelberg; Vibha Tandon; Dulal Panda; Michelle D Reid; Ritu Aneja
Journal:  Bioorg Med Chem Lett       Date:  2015-03-31       Impact factor: 2.823

6.  Microtubule-associated protein 2, a marker of neuronal differentiation, induces mitotic defects, inhibits growth of melanoma cells, and predicts metastatic potential of cutaneous melanoma.

Authors:  Mohammad H Soltani; Rita Pichardo; Ziqui Song; Namrata Sangha; Fabian Camacho; Kapaettu Satyamoorthy; Omar P Sangueza; Vijayasaradhi Setaluri
Journal:  Am J Pathol       Date:  2005-06       Impact factor: 4.307

7.  The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase.

Authors:  Adam I Marcus; Jun Zhou; Aurora O'Brate; Ernest Hamel; Jason Wong; Michael Nivens; Adel El-Naggar; Tso-Pang Yao; Fadlo R Khuri; Paraskevi Giannakakou
Journal:  Cancer Res       Date:  2005-05-01       Impact factor: 12.701

8.  Farnesyl transferase expression determines clinical response to the docetaxel-lonafarnib combination in patients with advanced malignancies.

Authors:  John Kauh; Chantal Chanel-Vos; Daniel Escuin; Michael P Fanucchi; R Donald Harvey; Nabil Saba; Dong M Shin; Anthony Gal; Lin Pan; Michael Kutner; Suresh S Ramalingam; Laura Bender; Adam Marcus; Paraskevi Giannakakou; Fadlo R Khuri
Journal:  Cancer       Date:  2011-03-01       Impact factor: 6.860

Review 9.  Targeting microtubules by natural agents for cancer therapy.

Authors:  Eiman Mukhtar; Vaqar Mustafa Adhami; Hasan Mukhtar
Journal:  Mol Cancer Ther       Date:  2014-01-16       Impact factor: 6.261

10.  Oncogenic BRAFV600E induces expression of neuronal differentiation marker MAP2 in melanoma cells by promoter demethylation and down-regulation of transcription repressor HES1.

Authors:  Nityanand Maddodi; Kumar M R Bhat; Sulochana Devi; Su-Chun Zhang; Vijayasaradhi Setaluri
Journal:  J Biol Chem       Date:  2009-10-30       Impact factor: 5.157
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.